| Literature DB >> 31797199 |
Richard L Applegate Ii1,2, Patricia M Applegate3, Maxime Cannesson4,5, Prith Peiris6, Beth L Ladlie6, Klaus Torp6.
Abstract
Transfusion decisions are guided by clinical factors and measured hemoglobin (Hb). Time required for blood sampling and analysis may cause Hb measurement to lag clinical conditions, thus continuous intraoperative Hb trend monitoring may provide useful information. This multicenter study was designed to compare three methods of determining intraoperative Hb changes (trend accuracy) to laboratory determined Hb changes. Adult surgical patients with planned arterial catheterization were studied. With each blood gas analysis performed, pulse cooximetry hemoglobin (SpHb) was recorded, and arterial blood Hb was measured by hematology (tHb), arterial blood gas cooximetry (ABGHb), and point of care (aHQHb) analyzers. Hb change was calculated and trend accuracy assessed by modified Bland-Altman analysis. Secondary measures included Hb measurement change direction agreement. Trend accuracy mean bias (95% limits of agreement; g/dl) for SpHb was 0.10 (- 1.14 to 1.35); for ABGHb was - 0.02 (- 1.06 to 1.02); and for aHQHb was 0.003 (- 0.95 to 0.95). Changes more than ± 0.5 g/dl agreed with tHb changes more than ± 0.25 g/dl in 94.2% (88.9-97.0%) SpHb changes, 98.9% (96.1-99.7%) ABGHb changes and 99.0% (96.4-99.7%) aHQHb changes. Sequential changes in SpHb, ABGHb and aHQHb exceeding ± 0.5 g/dl have similar agreement to the direction but not necessarily the magnitude of sequential tHb change. While Hb blood tests should continue to be used to inform transfusion decisions, intraoperative continuous noninvasive SpHb decreases more than - 0.5 g/dl could be a good indicator of the need to measure tHb.Entities:
Keywords: Hemoglobin; Intraoperative monitoring; Noninvasive measurement; Point of care tests
Mesh:
Substances:
Year: 2019 PMID: 31797199 PMCID: PMC7447626 DOI: 10.1007/s10877-019-00428-3
Source DB: PubMed Journal: J Clin Monit Comput ISSN: 1387-1307 Impact factor: 2.502
Patient characteristics
| Patient characteristics | All | LLU | MCF | UCI |
|---|---|---|---|---|
| Sex # (%) | ||||
| Female | 70 (51.9%) | 29 (58.0%) | 26 (44.1%) | 15 (51.9%) |
| Male | 65 (48.1%) | 21 (42.0%) | 33 (55.9%) | 11 (42.3%) |
| Age years | 61 [50–69] | 58.5 [44.5–68.5] | 63 [54–70] | 58.5 [47.8–68.3] |
| Weight kg | 79.3 [66.1–96.2] | 79.6 [64.9–98.9] | 79.3 [66.6–92.6] | 76.9 [64.6–96.4] |
| Body mass index kg m−2 | 28.0 [24.0–32.7] | 28.0 [24.5–35.0] | 28.1 [23.8–29.9] | 27.9 [22.7–33.2] |
| Number of samples per patient | 4 | 4 | 4 | 4 |
| Range | [3–5] 2–13 | [3–5] 2–6 | [2–6] 2–13 | [4–4] 2–4 |
1st intraoperative hemoglobin g/dl Range | 10.8 [9.1–11.9] 5.9–14.7 | 10.8 [9.3–11.9] 5.9–14.7 | 10.1 [8.6–11.7] 6.8–13.8 | 11.7a [10.3–12.9] 9.1–13.8 |
Intraoperative hemoglobin g/dl Range | 10.1 [8.9–11.5] 4.9–14.7 | 10.0 [8.7–11.3] 4.9–14.7 | 9.5 [8.6–11.0] 5.9–14.1 | 11.5 [10.3–12.5] 8.4–14.3b |
Sequential change in laboratory hemoglobin g/dl Range | − 0.1 [− 0.6 to 0.4] − 5.0 to 3.7 | 0.3 [− 0.8 to 0.3] − 5.0 to 3.2d | 0 [− 0.7 to 0.5] − 3.3 to 3.7 | 0 [− 0.2 to 0.3] − 3.3 to 0.9 |
| Duration of monitoring minutes | 302 [181–390] | 335 [257–386] | 354 [266–437] | 88c [79–101] |
| Surgical procedure type # | ||||
| Major abdominal | 58 | 19 | 26 | 13 |
| Liver resection or transplant | 25 | 3 | 17 | 5 |
| Major orthopedic | 16 | 8 | 5 | 23 |
| Major urologic | 16 | 3 | 11 | 2 |
| Major gynecologic | 12 | 11 | 0 | 1 |
| Major vascular | 6 | 6 | 0 | 0 |
| Major neurosurgical | 2 | 0 | 0 | 2 |
Characteristics of patients undergoing surgery with arterial catheterization at one of 3 academic medical centers: LLU Loma Linda University; MCF Mayo Clinic in Florida; UCI University of California Irvine. Results are median [25th to 75th percentile] except sex and procedure type which are number (%)
aFirst intraoperative hemoglobin higher at UCI than LLU (Hodges Lehman difference 0.9; 0.1–0.8 g/dl p = 0.03) and MCF (Hodges Lehman difference 1.3; 0.5–2.2 g/dl p = 0.003)
bIntraoperative hemoglobin higher at UCI than LLU (Hodges Lehman difference 1.4; 1.0–1.8 g/dl) and MCF (Hodges Lehman difference 1.7; 1.3–2.1 g/dl) both p < 0.0001
cDuration of monitoring less at UCI than LLU (Hodges Lehman difference − 237; − 268 to − 201 min) and MCF (Hodges Lehman difference − 264; − 298 to − 225 min) both p < 0.0001
dSequential change more negative at LLU than MCF (Hodges Lehman L difference − 0.2; − 0.4 to 0 g/dl; p = 0.04) and UCI (Hodges Lehman difference − 0.3; − 0.4 to − 0.1 g/dl; p = 0.006)
Fig. 1Modified Bland–Altman analysis of trend accuracy comparing 416 sequential changes in laboratory hematology analyzer hemoglobin (tHb) to the difference between tHb changes and paired sequential changes in top panel: pulse cooximetry hemoglobin (SpHb); middle panel: arterial blood gas cooximetry hemoglobin (ABGHb) and bottom panel: Hemocue point of care hemoglobin using arterial blood (aHQHb). Horizontal dotted lines indicate 95% limits of agreement (± 1.96 SD)
Fig. 2Clinical acceptability plot of absolute accuracy comparing hemoglobin determined by laboratory hematology analyzer (tHb) to hemoglobin determined by top panel: pulse cooximetry (SpHb); middle panel: arterial blood gas cooximetry (ABGHb) and bottom panel: Hemocue point of care using arterial blood (aHQHb). Compared to results for tHb: zone A indicates results within a clinically acceptable range (± 10%) at lower tHb; zone B indicates results that could represent a clinically significant error; and zone C indicates a potentially dangerous error in results from SpHb, ABGHb or aHQHb [12, 13]
Agreement of trend direction between tHb change more than ± 0.25 g/dl and SpHb, ABGHb and aHQHb change more than ± 0.5 g/dl
| Same direction as tHb trend | Not the same direction as tHb trend | |
|---|---|---|
| Increase | ||
| SpHb | 61 (92.4%; 83.5–96.7%) | 5 (7.6%; 3.3–16.5%) |
| ABGHb | 76 (97.4%; 91.1–99.3%) | 2 (2.6%; 0.7–8.9%) |
| aHQHb | 84 (100%; 95.6–100%) | 0 |
| Decrease | ||
| SpHb | 68 (97.8%; 88.3–98.6%) | 3 (4.2%; 1.4–11.7%) |
| ABGHb | 103 (100%; 96.4–100%) | 0 |
| aHQHb | 111 (98.2%; 93.8–99.5%) | 2 (1.8%; 0.5–6.2%) |
Fig. 3Four quadrant plots of changes in laboratory hemoglobin (tHb) compared to changes in hemoglobin determined by left panel: pulse cooximetry (SpHb); middle panel: arterial blood gas cooximetry (ABGHb) and right panel: point of care device using arterial blood (aHQHb). Dotted lines show limits of exclusion zones of ± 0.5 g/dl for SpHb, ABGHb and aHQHb and ± 0.25 g/dl for tHb based on repeated analysis of blood samples
Fig. 4Four quadrant plots of changes in laboratory hemoglobin (tHb) when tHb < 9.0 g/dl compared to changes in hemoglobin determined by left panel: pulse cooximetry (SpHb); middle panel: arterial blood gas cooximetry (ABGHb) and right panel: point of care device using arterial blood (aHQHb). Dotted lines show limits of exclusion zones of ± 0.5 g/dl for SpHb, ABGHb and aHQHb and ± 0.25 g/dl for tHb based on repeated analysis of blood samples